Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations

Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations

Lung adenocarcinoma (LUAD) is the most prevalent subtype of non‐small cell lung cancer. Despite the development of novel targeted and immune therapies, the 5‐year survival rate is still only 21%, indicating the need for more efficient treatment regimens. Lysine‐specific demethylase 1 (LSD1) is an ep...

Full description

Bibliographic Details
Main Authors: Iris F. Macheleidt, Priya S. Dalvi, So‐Young Lim, Sonja Meemboor, Lydia Meder, Olivia Käsgen, Marion Müller, Karolin Kleemann, Lingyu Wang, Peter Nürnberg, Vanessa Rüsseler, Stephan C. Schäfer, Esther Mahabir, Reinhard Büttner, Margarete Odenthal
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Molecular Oncology
Subjects:
epigenetic alterations
HCI‐2509
histone methylation
KDM1A
LSD1
lung adenocarcinoma
Online Access:https://doi.org/10.1002/1878-0261.12382

Internet

https://doi.org/10.1002/1878-0261.12382

Similar Items